| 0 (0%) | 09-27 09:31 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.79 | 1-year : | 3.95 |
| Resists | First : | 2.39 | Second : | 3.39 |
| Pivot price | 0.99  |
|||
| Supports | First : | 0.79 | Second : | 0.65 |
| MAs | MA(5) : | 0.97 |
MA(20) : | 0.97 |
| MA(100) : | 1.73 |
MA(250) : | 2.34 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 34.7 |
D(3) : | 39.1 |
| RSI | RSI(14): 35.6 |
|||
| 52-week | High : | 6.98 | Low : | 0.79 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ OTLK ] has closed above bottom band by 34.7%. Bollinger Bands are 78.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.99 - 1 | 1 - 1 |
| Low: | 0.94 - 0.95 | 0.95 - 0.95 |
| Close: | 0.96 - 0.97 | 0.97 - 0.98 |
Mon, 22 Sep 2025
New Analyst Forecast: $OTLK Given $8.0 Price Target - Quiver Quantitative
Sun, 21 Sep 2025
Outlook Therapeutics, Inc.(NasdaqCM: OTLK) dropped from S&P Global BMI Index - MarketScreener
Tue, 02 Sep 2025
FDA Requests Additional Efficacy Data: Outlook Therapeutics Plans Meeting on Wet-AMD Drug ONS-5010 - Stock Titan
Fri, 29 Aug 2025
OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug - Zacks Investment Research
Thu, 28 Aug 2025
US FDA declines to approve Outlook Therapeutics' eye disease drug, shares plummet - Reuters
Thu, 28 Aug 2025
Why Did Outlook Therapeutics (OTLK) Shares Crash Today? - Tokenist
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 44 (M) |
| Held by Insiders | 2.506e+007 (%) |
| Held by Institutions | 36.3 (%) |
| Shares Short | 2,350 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.251e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 46.2 % |
| Return on Equity (ttm) | -130.7 % |
| Qtrly Rev. Growth | 1.51e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -8.23878e+007 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -56 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.56 |
| Dividend | 0 |
| Forward Dividend | 6.81e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|